After receiving an A.B. in Biochemical Sciences and a Ph.D. in Bacteriology from Harvard University, Dr. Ohlsson-Wilhelm carried out post-doctoral research in Biophysics at the University of Chicago and in Somatic Cell Genetics at the Institute for Cancer Research (now the Fox Chase Cancer Center). Over a 20-year career in academic medicine, she held senior faculty positions in microbiology, immunology, genetics, and medicine (endocrinology) at the University of Rochester, School of Medicine and Dentistry, and the Pennsylvania State University, College of Medicine at Hershey. Dr. Ohlsson-Wilhelm was subsequently recruited by Zynaxis, Inc., a startup company developing site-selective delivery systems where she rose to Sr. V.P. of R&D, with responsibility for programs related to development of improved antineoplastics, antirheumatics and infectious disease vaccines. In 1996, she and Dr. Katharine Muirhead co-founded SciGro, a biomedical consultancy that works with inventors, entrepreneurs, and investors to translate scientific discoveries and early stage technologies into successful research tools and products for the pharmaceutical, biotechnology, medical diagnostics and life sciences industries. Her research interests include: cell-based assays and therapies; applications involving flow and/or image cytometry; drugs and vaccines to treat cancer, immune-based diseases, infectious diseases and neurological diseases and a variety of medical devices.